1. 10PCirculating miR-652-3p as a biomarker of drug resistance in metastatic colorectal cancer patients. (7th November 2019) Authors: Hedayat, S; Lampis, A; Vlachogiannis, G; Khan, K; Cunningham, D; Marchetti, S; Fassan, M; Begum, R; Schirripa, M; Loupakis, F; Valeri, N Journal: Annals of oncology Issue: Volume 30(2019)Supplement 7 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 147P A personalised approach for anti-GITR-based immunotherapy in pre-clinical models of pancreatic ductal adenocarcinoma. (15th December 2019) Authors: Desai, K; Ragulan, C; Lawrence, P V; Wullschleger, S; Tichet, M L; Box, G; Fontana, E; Young, K; Larkin, J M J; Hanahan, D; Cunningham, D; Starling, N; Sadanandam, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 14PModulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of response to DNA damage. (7th November 2019) Authors: Lampis, A; Carotenuto, P; Hedayat, S; Previdi, M C; Zito, D; Sclafani, F; Parisi, C; Hahne, J C; Hallsworth, A; Kirkin, V; Young, K; Kouvelakis, K; Azevedo, S X; Vasiliki, M; Scarpa, A; Cunningham, D; Chau, I; Valeri, N; Fassan, M; Braconi, C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 7 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1867PCirculating tumour DNA (ctDNA) as a tool to assess response and guide therapy adaptation in rectal cancer. (23rd October 2018) Authors: Khakoo, S; Carter, P; Valeri, N; Shaikh, R; Jones, T; Begum, R; Rana, I; Picchia, S; Bali, M; Brown, G; Wotherspoon, A; Terlizzo, M; von Loga, K; Ahmed, I; Watkins, D; Chau, I; Starling, N; Tait, D; Hubank, M; Cunningham, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 187: EFFECT OF PERI-OPERATIVE CHEMOTHERAPY REGIMEN ON SURVIVAL IN THE TREATMENT OF LOCALLY ADVANCED GASTRO-OESOPHAGEAL ADENOCARCINOMA—FLOT VS 'MAGIC'. (23rd April 2022) Authors: Moore, J; Kumar, S; Patel, P; Santaollala, A; Kapiris, M; Van Hemelrijk, M; Maisey, N; Lagergren, J; Gossage, J; Kelly, M; Baker, C; Allum, W; Cunningham, D; Davies, A Journal: Diseases of the esophagus Issue: Volume 35(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 1OKRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies. (23rd October 2018) Authors: Georgiou, A; Stewart, A; Thavasu, P; Coker, E A; Poelsterl, S; Al-Lazikani, B; Cunningham, D; Whittaker, S; Banerji, U Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 619PD_PRInfluence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: A pooled analysis of four randomised trials. (23rd October 2018) Authors: Davidson, M; Wagner, A D; Kouvelakis, K; Starling, N; Chau, I; Watkins, D; Rao, S; Peckitt, C; Cunningham, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 637PMagnetic resonance imaging in oesophageal (oes) cancer: Results from the STO3 MRI substudy. (23rd October 2018) Authors: Davidson, M; Nankivell, M; Cunningham, D; Starling, N; Koh, D-M; Brown, G; Allum, W; Wotherspoon, A; Smyth, E; Ly, L; Kleovoulou, N; Langley, R; Riddell, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 646PEGFR amplification (amp) and survival in the REAL-3 trial. (23rd October 2018) Authors: Smyth, E; Kouvelakis, K; Cunningham, D; Hahne, J C; Peckitt, C; Vlachogiannis, G; Watkins, D; Rao, S; Starling, N; Wilson, S H; Waddell, T S; Okines, A; Crosby, T; Mansoor, W; Wadsley, J; Middleton, G; Wotherspoon, A; Chau, I; Valeri, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 666TiPA phase Ib/ II trial to assess the safety and efficacy of CXD101 in combination with the PD-1 inhibitor nivolumab in patients with metastatic, previously-treated, microsatellite-stable (MSS) colorectal carcinoma (short title CAROSELL). (1st October 2019) Authors: Saunders, M P; Graham, J; Cunningham, D; Plummer, R; Cook, S; Church, D; Kerr, R; Thangue, N La; Kerr, D J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗